1. Home
  2. SNSC vs SCYX Comparison

SNSC vs SCYX Comparison

Compare SNSC & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SNSC

SunScout Holding Limited Class A Ordinary Shares

N/A

Current Price

$1.08

Market Cap

51.4M

Sector

N/A

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$5.15

Market Cap

51.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNSC
SCYX
Founded
N/A
1999
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.4M
51.4M
IPO Year
2026
2014

Fundamental Metrics

Financial Performance
Metric
SNSC
SCYX
Price
$1.08
$5.15
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
665.1K
78.7K
Earning Date
N/A
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$0.57
52 Week High
$3.07
$6.09

Technical Indicators

Market Signals
Indicator
SNSC
SCYX
Relative Strength Index (RSI) 19.78 53.50
Support Level N/A $4.65
Resistance Level $1.70 $5.56
Average True Range (ATR) 0.30 0.34
MACD -0.04 -0.05
Stochastic Oscillator 4.19 16.51

Price Performance

Historical Comparison
SNSC
SCYX

About SNSC SunScout Holding Limited Class A Ordinary Shares

SunScout Holding Ltd is a clean-technology company engaged in the design, development, manufacturing, and commercialization of autonomous, solar-powered robotic mowers and related solar energy solutions. Its products are intended as alternatives to petrol-powered and grid-dependent electric lawn mowing equipment. The company's business comprises three lines of products and solutions, which are also its reportable segments: SunScout Products, Solar Power Development Solutions, and Engineering Products and Services. The majority of revenue is derived from the Solar Power Development Solutions segment, which develops and installs solar-energy systems for commercial, industrial, and institutional customers through EPC contracts. Geographically, maximum revenue is derived from New Zealand.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: